Navigation Links
Kimberly-Clark Acquires Baylis Medical Company's Pain Management Business
Date:10/5/2009

DALLAS, Oct. 5 /PRNewswire-FirstCall/ -- Kimberly-Clark Corporation (NYSE: KMB) announced today that it has acquired Baylis Medical Company's pain management business, which includes a number of innovative, minimally-invasive radio-frequency pain management products. Kimberly-Clark's Health Care business has been the exclusive distributor of Baylis Medical's pain management products in the U.S. since 2001.

The acquisition improves the competitive position of Kimberly-Clark Health Care in the $2 billion global market for minimally invasive chronic spinal pain management. Financial terms of the transaction were not disclosed.

"The acquisition of Baylis Medical's pain management business is consistent with our global business plan strategy to invest in the higher-growth, higher-margin medical device market," said Joanne Bauer, president, Kimberly-Clark Health Care. "This transaction will enable us to accelerate the growth of our pain management business around the world while strengthening our commitment to patients suffering from chronic spinal pain. Together with Baylis Medical, we're enhancing patients' quality of life through minimally invasive, radio-frequency therapies."

Baylis Medical President Frank Baylis said that today's announcement is a logical move for both companies. "We are very excited about Kimberly-Clark's acquisition of Baylis Medical's pain management business. We've enjoyed an excellent and mutually beneficial working relationship over the last eight years and integrating our technology with Kimberly-Clark's global resources makes for a unique and powerful offering in the pain management category," he said.

About Kimberly-Clark and Kimberly-Clark Health Care

Kimberly-Clark and its well-known global brands are an indispensable part of life for people in more than 150 countries. To learn more about Kimberly-Clark and its 137-year history of innovation, visit www.kimberly-clark.com.

Around the world, medical professionals turn to Kimberly-Clark for a wide portfolio of solutions that improve the health, hygiene and well-being of their patients and staff. As part of their healing mission, caregivers rely on Kimberly-Clark Health Care to deliver clinical solutions and educational resources that they can depend on to prevent, diagnose and manage a wide variety of healthcare-associated infections. This over $1 billion global enterprise of Kimberly-Clark Corporation holds the No. 1 and No. 2 market share positions in several categories including infection control solutions, surgical solutions, pain management and digestive health. And throughout the care continuum, patients and staff alike trust Kimberly-Clark* medical supplies and devices, Kleenex tissues, Kimberly-Clark* professional skin care products, and Scott towels for day-to-day needs. For more information, please visit http://www.kchealthcare.com.

About Baylis Medical Company

Baylis is a leading developer, manufacturer and supplier of high-technology medical devices for chronic pain management, interventional cardiology, and radiology. Founded in 1986 in Montreal, Quebec, Baylis has grown to have offices across Canada as well as in the United Kingdom and Asia. The company's research, development and manufacturing departments are located in Mississauga, Ontario. Baylis presently employs over 130 staff and markets its products in over 60 countries. Baylis Medical's vision is to bring to market state-of-the-art medical products that will improve the lives of people around the world.

Certain matters contained in this news release concerning the business outlook, including expected savings, anticipated financial and operating results, strategies, contingencies and anticipated transactions of the company constitute forward-looking statements and are based upon management's expectations and beliefs concerning future events impacting the company. There can be no assurance that these future events will occur as anticipated or that the company's results will be as estimated. For a description of certain factors that could cause the company's future results to differ materially from those expressed in any such forward-looking statements, see Item 1A of the company's Annual Report on Form 10-K for the year ended December 31, 2008 entitled "Risk Factors."

SOURCE Kimberly-Clark Corporation


'/>"/>
SOURCE Kimberly-Clark Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
2. Wound Management Technologies Acquires Resorbable Orthopedics
3. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
4. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
5. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
6. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. U.S. Preventive Medicine Acquires Specialty Disease Management
9. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 This ... US$ Thousand. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:2/23/2017)... England and DEERFIELD, Ill. ... U.S.A. , Inc., a wholly-owned subsidiary of ... a joint venture between Cambridge Cognition Holdings PLC and ... use of a specially designed app on an Apple ... patients with Major Depressive Disorder (MDD). Depression ...
(Date:2/23/2017)... , Feb. 23, 2017  CTI BioPharma Corp. ... management plans to report its fourth quarter and full ... the close of the U.S. financial markets. Following the ... webcast conference call to discuss the results and provide ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only ... their upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October ... the Virginia Mason Health System in Seattle since 2000. In addition to his role ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® ... of individuals who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent ... California, where they are free from the shame, stigma, and harmful labeling ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well ... solution helps transform the HCC Risk Adjustment process from a typical fragmented ...
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
Breaking Medicine News(10 mins):